EA201990158A1 - Производные бензодиоксана и их фармацевтическое применение - Google Patents

Производные бензодиоксана и их фармацевтическое применение

Info

Publication number
EA201990158A1
EA201990158A1 EA201990158A EA201990158A EA201990158A1 EA 201990158 A1 EA201990158 A1 EA 201990158A1 EA 201990158 A EA201990158 A EA 201990158A EA 201990158 A EA201990158 A EA 201990158A EA 201990158 A1 EA201990158 A1 EA 201990158A1
Authority
EA
Eurasian Patent Office
Prior art keywords
benzodioxane
derivatives
pharmaceutical application
alpha2c
pharmaceutical
Prior art date
Application number
EA201990158A
Other languages
English (en)
Inventor
Ансси Хайкарайнен
Эса Кумпулаинен
Антти Похякаллио
Ярмо Пюстюнен
Шоумин Ван
Original Assignee
Орион Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Орион Корпорейшн filed Critical Орион Корпорейшн
Publication of EA201990158A1 publication Critical patent/EA201990158A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Соединения формулы Iгде Rи Rимеют значения, определенные в формуле изобретения, проявляют альфа2C-антагонистическую активность и, таким образом, могут применяться в качестве альфа2C-антагонистов.
EA201990158A 2016-06-29 2017-06-28 Производные бензодиоксана и их фармацевтическое применение EA201990158A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20165536 2016-06-29
PCT/FI2017/050484 WO2018002437A1 (en) 2016-06-29 2017-06-28 Benzodioxane derivatives and their pharmaceutical use

Publications (1)

Publication Number Publication Date
EA201990158A1 true EA201990158A1 (ru) 2019-05-31

Family

ID=59501477

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990158A EA201990158A1 (ru) 2016-06-29 2017-06-28 Производные бензодиоксана и их фармацевтическое применение

Country Status (12)

Country Link
US (1) US20190152992A1 (ru)
EP (1) EP3478676A1 (ru)
JP (1) JP2019519582A (ru)
KR (1) KR20190020343A (ru)
CN (1) CN109415355A (ru)
AU (1) AU2017287919A1 (ru)
CA (1) CA3029109A1 (ru)
EA (1) EA201990158A1 (ru)
IL (1) IL263969A (ru)
MX (1) MX2018015872A (ru)
WO (1) WO2018002437A1 (ru)
ZA (1) ZA201808060B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3543231A1 (en) * 2018-03-19 2019-09-25 ETH Zurich Compounds for treating cns- and neurodegenerative diseases
EP3810592A1 (en) * 2018-06-20 2021-04-28 Janssen Pharmaceutica NV Oga inhibitor compounds
CN112292377A (zh) * 2018-06-20 2021-01-29 詹森药业有限公司 Oga抑制剂化合物
AU2019291097A1 (en) * 2018-06-20 2020-12-17 Janssen Pharmaceutica Nv OGA inhibitor compounds
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
WO2024084360A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622569A (en) 1969-08-05 1971-11-23 R & L Molecular Research Ltd 6-(2-aryl-3-azido-and-3-amino-methyl-isocrotonamido)penicillanic acids
GB2167408B (en) 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
CA2156177C (en) 1993-02-16 2003-05-20 Ube Industries, Ltd. Quinoline derivatives as thromboxane a2 and leukotriene d4 antagonists
US5703115A (en) * 1993-02-19 1997-12-30 Janssen Pharmaceutica, N.V. (benzodioxan, benzofuran or benzopyran) alkylamino! alkyl substituted guanidines
GB9318431D0 (en) 1993-09-06 1993-10-20 Boots Co Plc Therapeutic agents
GB9409944D0 (en) 1994-05-17 1994-07-06 Rhone Poulenc Agriculture New compositions of matter
JPH11180979A (ja) * 1997-10-17 1999-07-06 Hokuriku Seiyaku Co Ltd 環状アミン誘導体
US7202279B1 (en) 1998-02-11 2007-04-10 Georgetown University Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
FR2795727B1 (fr) * 1999-06-29 2001-09-21 Pf Medicament Nouveaux derives benzodioxanne imidazolines fluores, leur preparation et leurs applications en therapeutique
ATE374773T1 (de) 2002-04-03 2007-10-15 Orion Corp Polycyclische verbindungen als potenten alpha2- adrenoceptor antagonisten
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
BRPI0610046A2 (pt) * 2005-04-22 2010-05-25 Wyeth Corp derivados de benzodioxano e benzodioxolano e usos destes
PE20071240A1 (es) 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
KR20090047509A (ko) 2006-08-04 2009-05-12 다케다 야쿠힌 고교 가부시키가이샤 융합 헤테로시클릭 유도체 및 이의 용도
WO2008094575A2 (en) 2007-01-30 2008-08-07 Biogen Idec Ma Inc. 1-h-pyrazolo(3,4b)pyrimidine derivatives and their use as modulators of mitotic kinases
TWI457122B (zh) * 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
TW201024282A (en) * 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
WO2011085261A1 (en) 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors
AR104882A1 (es) * 2015-06-05 2017-08-23 Orion Corp DERIVADOS DE 2-(1-HETEROARILPIPERAZIN-4-IL)METIL-1,4-BENZODIOXANO COMO ANTAGONISTAS DE a2C

Also Published As

Publication number Publication date
WO2018002437A1 (en) 2018-01-04
EP3478676A1 (en) 2019-05-08
AU2017287919A1 (en) 2019-01-17
MX2018015872A (es) 2019-04-22
US20190152992A1 (en) 2019-05-23
IL263969A (en) 2019-01-31
ZA201808060B (en) 2019-08-28
KR20190020343A (ko) 2019-02-28
CA3029109A1 (en) 2018-01-04
CN109415355A (zh) 2019-03-01
JP2019519582A (ja) 2019-07-11

Similar Documents

Publication Publication Date Title
CO2017011754A2 (es) Amidas heterocíclicas como inhibidores de quinasa
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
EA201990158A1 (ru) Производные бензодиоксана и их фармацевтическое применение
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201691913A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
EA201891622A1 (ru) Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их
EA201890126A1 (ru) Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
GEP20186887B (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
EA201691194A1 (ru) Стимуляторы ргц
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201692525A1 (ru) Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов
EA201990044A1 (ru) Гетероциклические соединения в качестве антибактериальных средств
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
ECSP18024565A (es) Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
CL2015002897A1 (es) Inhibidores de bace1
EA201790939A1 (ru) ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2
EA201591397A1 (ru) Хиноксалиноны и дигидрохиноксалиноны как антивирусные средства против респираторно-синцитиального вируса